Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiri...

por Garber, A, Henry, R R, Ratner, R, Hale, P, Chang, C T, Bode, B
Publicado 2011

Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target stud...

por Kumar, S., Jang, H. C., Demirağ, N. G., Skjøth, T. V., Endahl, L., Bode, B.
Publicado 2016

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes

por Bowering, K., Harvey, J., Kolaczynski, J. W., Snyder, J. W., Bode, B. W.
Publicado 2018

Efficacy and safety of an oral device to reduce food intake and promote weight loss

por Ryan, D. H., Parkin, C. G., Longley, W., Dixon, J., Apovian, C., Bode, B.
Publicado 2017

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL...

por Rodbard, H. W., Bode, B. W., Harris, S. B., Rose, L., Lehmann, L., Jarlov, H., Thurman, J.
Publicado 2016

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with t...

por Bode, B W, Testa, M A, Magwire, M, Hale, P M, Hammer, M, Blonde, L, Garber, A
Publicado 2010

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

por Ratner, R E, Gough, S C L, Mathieu, C, Del Prato, S, Bode, B, Mersebach, H, Endahl, L, Zinman, B
Publicado 2013

One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial...

por Gough, S. C. L., Bode, B. W., Woo, V. C., Rodbard, H. W., Linjawi, S., Zacho, M., Reiter, P. D., Buse, J. B.
Publicado 2015

Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin asp...

por Bode, B W, Buse, J B, Fisher, M, Garg, S K, Marre, M, Merker, L, Renard, E, Russell-Jones, D L, Hansen, C T, Rana, A, Heller, S R
Publicado 2013